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Abstract
Background: Previous studies have shown that excessive abdominal visceral adipose tissue (AVAT) and epicardial
adipose tissue (EAT) are risk factors of cardiometabolic disease; we hypothesized there is differential contribution of
abdominal and cardiac fat deposits to the cardiometabolic profiles.
Methods: Two hundred eight consecutive subjects with clinical suspicion of coronary artery disease (CAD) who
underwent cardiac and abdominal CT for Agatston score and abdominal visceral fat measurement were
retrospectively analyzed. Regional thickness of EAT (EATth), total volume of EAT, total volume of paracardial adipose
tissue (PAT) and total volume of AVAT from L2 to L5 level were measured. The relationships between abdominal
and cardiac adipose tissue measurements, the number of components of metabolic syndrome, and the severity of
Agatston score on a four ranking scale (0, 1–10,11–100, 101–400, >400) were investigated.
Results: The amounts of AVAT, EAT, PAT and EATth-LAVG showed a significant linear trend with increasing number
(0–5) of components in metabolic syndrome (AVAT, EAT and PAT P for trend <0.0001; EATth-LVAG P for trend
<0.001). EATth at left atrioventricular groove (EATth-LAVG) showed significant linear trend with the severity of
Agatston score on a four ranking scale (P for trend <0.0001). In multivariate binary regression analysis, total volume
of AVAT was the sole adiposity predictor for metabolic syndrome independent to age, gender, and waist
circumference (odds ratio of 1.20, 95 % CI 1.08–1.32, p < 0.001) while total volume of EAT, PAT, and EATth-LAVG
were not. In contrary, EATth-LAVG was the sole adiposity predictor for Agatston score >400 (odds ratio of 1.11,
95 % CI 1.034–1.184, p = 0.004).
Conclusions: Excessive total volume of AVAT appears to be preferentially associated with metabolic syndrome;
while EAT, esp. EATth-LAVG is preferentially associated with coronary artery disease. This differential effect of the
two adiposities deserves a large-scale cohort study for further investigation.
Keywords: Ectopic fat deposits, Cardiometabolic risks
Background
Visceral adiposity has been increasingly recognized as a
well-established risk marker of cardiometabolic disease
[1–4]. Visceral adiposity, as an endocrine organ, secretes
different adipokines, including cytokines and chemo-
kines, which can have systemic effects [5–7]. Distribu-
tion of ectopic fat is considered as an important
predictor of cardiometabolic risks. Different distributions
of excessive ectopic fat deposits in various locations in-
cluding the liver, muscle, kidneys, heart, subcutaneous
region and abdomen may be associated with differential
impacts on cardiometabolic risks [5, 8]. These site-
specific differences of ectopic fat depots are therefore
important in understanding the role of visceral adiposity
as a causal factor in cardiometabolic risks. Previous
studies have highlighted the association between abdom-
inal visceral fat and cardiometabolic risks [9–11],
abdominal subcutaneous fat and metabolic syndromes
[10, 12, 13], epicardial adipose tissue (EAT) adiposity
and CAD risks [14–16], and regional-specific EAT
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adiposity with cardiometabolic risks [17, 18]. Abdominal
visceral fat is believed to be intrinsically different from
cardiac visceral fat. Both excessive abdominal adiposity
and cardiac adiposity are essential contributors to the
development of the cardiometabolic risks. Although they
tend to occur together, their quantitative relationship
and their respective roles in various cardiometabolic
components remain unclear. To the best of our know-
ledge, none of these studies provided comprehensive
quantitative estimates of the relative contribution to the
cardiometabolic risks of abdominal fat (including ab-
dominal visceral fat and abdominal subcutaneous fat)
and cardiac fat (including epicardial, pericardial and
regional-specific cardiac fat). There is thus a lack of
studies specifically aiming at systematic investigation,
using precise measurement techniques, of the relative
importance of excessive abdominal and cardiac fat accu-
mulation in explaining the variation of the components
of the cardiometabolic risks. Our work is the first to sys-
tematically investigate the impacts of the differential ec-
topic fat deposits on cardiometabolic risks. In addition,
different types of regional-specific or total volume of
EAT depot may play differential roles in the progression
of coronary artery atherosclerosis; however, this issue
has not been well addressed [16, 18–20].
Methods
Study populations
A total of 208 consecutive subjects with clinical sus-
picion of CAD underwent EKG-gated coronary artery
calcification (CAC) scanning and non-contrast en-
hanced abdominal CT from January 2007 to June
2010 at our institution were retrospectively studied.
Complete medical histories including body mass index
(BMI), presence of hypertension and/or diabetes mel-
litus, smoking history and waist circumstance were
recorded for all participants. Blood levels of high-
density lipoprotein-cholesterol (HDL-C) and serum
triglyceride (TG) concentration were also recorded.
The study protocol was approved by the Institutional
Review Board Committee of Kaohsiung Veterans Gen-
eral Hospital, Kaohsiung, Taiwan. The requirement for
informed consent was waived.
CAC-scoring CT and assessment of Agatston score
CT scan was performed on a 64-detector raw CT scan-
ner (Aquilion 64, Toshiba Medical Systems, Tokyo,
Japan) with the following parameters: 64 × 0.5-mm colli-
mation, rotation time 350 ms, pitch factor 0.2–0.3, tube
voltage 120 kV, tube current 400 mA. Beta-adrenergic
antagonist (Metoprolol 50–100 mg, AstraZeneca, Hert-
fordshire, England) was orally administered 60 min be-
fore a scan if the patient’s heart rate ≥70 beats/min. The
Agatston scores were calculated using standard
quantification algorithms with semiautomatic software
(Vitrea 2; Vital Images, Minnetonka, MI, USA). Agatston
scores were further categorized into four ranks (0, 1–
100, 101–400, and >400) for CAD risk stratification.
Measurement of abdominal and cardiac adipose tissue
by CT
Abdominal (including abdominal subcutaneous fat and
abdominal visceral fat) and cardiac (including epicardial
fat volume, pericardial fat and regional epicardial fat
thickness) fat measurements were all performed on a
workstation (Advantage Workstation 4.3, GE Health-
care) as described in our previous studies shown in
Fig. 1(a-f ) [21]. Adipose tissue was defined as Hounsfield
units between −50 and −200, as previously reported
[22]. Total volume of abdominal visceral adipose tissue
(AVAT) was measured on axial images with a 0.5 mm
slice thickness at 8 mm intervals starting from L2 to L5
levels in each subject. EAT was defined as adipose tissue
located within the pericardial sac. Paracardial adipose
tissue (PAT) was defined as adipose tissue located out-
side the pericardial sac. Total volume of EAT and PAT
were measured on axial images starting from the level of
left main pulmonary artery to the left ventricular apex
with about 35 cross-section slices. EAT thickness was
measured at the left atrioventricular (AV) groove, right
AV groove and anterior AV groove, and abbreviated as
EATth-LAVG, EATth-RAVG and EATth-AIVG respect-
ively. Maximal fat thickness assessed as the distance
from myocardium to visceral epicardium in the orthog-
onal direction was determined [23]. Details regarding
measurements of EAT thickness and reproducibility for
all EAT measurements were described previously [21].
Characteristics of metabolic syndrome components
The metabolic syndrome components were defined ac-
cording to the criteria described by the National Choles-
terol Education Program Adult Treatment Panel III [24],
including (1) Presence of the abdominal obesity (waist
circumference ≥102 cm and ≥88 cm in men and women,
respectively); (2) elevated blood pressure (SBP
≥130 mmHg and/or DBP ≥85 mmHg); (3) low HDL-C
(<40 mg/dl and <50 mg/dl in men and women, respect-
ively); (4) TG ≥150 mg/dl, and (5) fasting plasma glucose
≥100 mg/dl (or current diabetic medication). All five
components of the metabolic syndrome were assessed,
and metabolic syndrome is diagnosed when a patient
has at least three of the five criteria.
Statistical analysis
The data for the continuous variables with a normal dis-
tribution are expressed as means ± SDs and the data for
the continuous variables without a normal distribution
are expressed as medians with interquartile ranges.
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To assess linear trends in various abdominal and car-
diac adipose tissue measurements for increasing num-
bers of metabolic syndrome components and the
severity of Agatston score, the general linear model con-
trolling for age and gender was used to test the linear
trend of measurements of abdominal and cardiac fat ac-
cording to the number of metabolic syndrome compo-
nents and the severity of Agatston score.
To determine different impacts of various abdominal
or cardiac adipose tissue measurements on cardiometa-
bolic risks, principal component analysis was used.
The resulting factor pattern was interpreted by using
factor loadings, and the most powerful factors (eigen
values >1.0) were retained for further analysis. To inter-
pret the results from factor analyses, the pattern of fac-
tor loadings was examined to determine which original
variables represent primary constituents of each factor.
An absolute loading value ≥0.40 was used to interpret
the resulting factor pattern.
Multivariate logistic regression analysis was used to
determine the relationships between the metabolic syn-
drome with abdominal and cardiac adiposity measure-
ments, including the total volume of EAT, PAT, AVAT
and EATth-LAVG after adjustment for age, gender and
waist circumference. Multivariate logistic regression
analysis was used to determine the relationships between
the severity of Agatston score with abdominal and car-
diac adiposity measurements, including the total volume
of EAT, PAT, AVAT and EATth-LAVG after adjustment
for age, gender, waist circumference, BMI, hypertension,
diabetes mellitus, HDL-C, triglycerides and current
smoker.
Results
Clinical characteristics of the study participants
We included 208 subjects (mean age 54.94 years,79 % male)
with detailed baseline characteristics and various adipose
tissue measurements demonstrated in Table 1. The BMI
and waist circumference were 24.90 ± 3.36 kg/m2 and
89.17 ± 8.90 cm respectively. 45 % were current smokers;
40 % had hypertension and 23 % had diabetes mellitus.
Correlations between cardiometabolic risk and adipose
tissue measurements
As shown in Fig. 2a, total volume of AVAT, EAT, PAT and
EATth-LAVG significantly increased as the number of the
metabolic syndrome components increased (p for trend
<0.001), whereas all other CT measurements of epicardial
thickeness including EATth-RAVG and EATth-AIVG did
not. On the other hand, the only EATth-LAVG was
Fig. 1 Quantification of different abdominal and cardiac fat deposits by CT with a threshold of −200 to −50 HU on a 3-dimensional workstation.
a Measurement of total pericardial fat volume by manual tracing (green boundary) of the area of the pericardial fat from the left main pulmonary
artery level to the left ventricular apex. b Measurement of total volume of EAT was performed on axial images by manual tracing (blue boundary)
of the parietal pericardium from the left main pulmonary artery level to the left ventricular apex. c Total volume of PAT (yellow boundary) = total
pericardial fat volume (PAT + EAT) – total EAT volume. d Measurement of total volume of AVAT was performed on axial images by manual tracing
(red boundary) of the parietal peritoneum from L2 to L5 levels. e Regional EAT thickness was assessed as the distance from myocardium in the
orthogonal direction to visceral epicardium on the horizontal long-axis plane at the left AVG, right AVG, and anterior IVG. f On the parasternal
short-axis plane, regional EAT thickness was measured at superior IVG, inferior IVG, and right ventricular (RV) free wall. Double-headed arrows
indicate the measurements of the EAT thickness. HU = Hounsfield units; EAT = epicardial adipose tissue; PAT = paracardial adipose tissue; AVAT =
abdominal visceral adipose tissue; AVG = atrioventricular groove; IVG = interventricular groove; RV = right ventricle
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significantly increased with the severity of Agatston score
on a four ranking scale (p for trend <0.001), whereas all
other CT measurements including total volume of AVAT,
EAT, and PAT, EATth-RAVG and EATth-AIVG did not
demonstrate significant correlation (Fig. 2b).
Pearson correlation coefficients between cardiometabolic
risk and adipose Tissue measurements
As shown in Table 2, total volume of AVAT, EAT, PAT
and EATth-LAVG were more positively and significantly
related to BMI, waist circumference and metabolic syn-
drome components, whereas the EATth- RAVG and
EATth- AIVG were not. Among the correlations be-
tween metabolic syndrome components and various
measurements of abdominal and cardiac adipose tissue,
we found the total volume of AVAT had the best correl-
ation (r = 0.519), followed by the total volume of EAT (r
= 0.382), the total volume of PAT (r = 0.264), and
EATth-LAVG (r = 0.250) (all p < 0.001).
Among all the EAT measurements, the EATth-LAVG
had the most significant correlation with BMI (r = 0.487,
P < 0.001) and metabolic syndrome components. The
total volume of AVAT and PAT had only weak correl-
ation with Agatston score ranking.
Among the correlations between Agatston socre and
various measurements of abdominal and cardiac adipose
tissue, we found the EATth-LAVG had the best correl-
ation (r = 287, P < 0.001), whereas the other CT mea-
surements including EATth-RAVG and EATth-AIVG
had no significant correlation.
Clustering of cardiometabolic risk factors: factor analysis
Table 3 displays the results of factor analysis of core
cardiometabolic variables among 208 subjects. The
factor-loading pattern of the two factors (components)
identified in the study is presented in Table 3. More im-
portantly, the factor 1 and factor 2 cumulatively ex-
plained 65.01 % of the total variation of cardiometabolic
risk in the study.
Factor 1 had strong contributions from BMI, waist cir-
cumference, metabolic syndrome components, total vol-
ume of AVAT, EAT and PAT. This factor was interpreted
as a “volumetric abdominal or cardiac adiposity-
metabolic factor” and explained 49.91 % of the total vari-
ance. Factor 2 had strong contributions from only two
components including Agatston score and EATth-
LAVG. This factor was interpreted as a “regional-specific
cardiac adiposity-CAD factor” and explained 15.10 % of
the total variance.
Abdominal or cardiac adiposity in cardiometabolic risk
factors
Table 4 shows the multivariate logistic regression ana-
lysis to determine the predictors of metabolic syndrome.
Total volume of AVAT is the most important sole inde-
pendent predictor of metabolic syndrome after adjusting
for age, gender and waist circumference (odds ratio of
1.20, 95 % CI 1.08–1.32, p < 0.001). In multivariate or-
dinal logistic regression analysis, EATth-LAVG is an in-
dependent predictor (odds ratio of 1.11, 95 % CI 1.034–
1.184, p = 0.004) for Agatston score >400 after adjusting
for age, gender, waist circumference, BMI, hypertension,
diabetes mellitus, HDL-C, triglycerides and current
cigarette use while other measurements of abdominal or
cardiac adipose tissue are not (summarized in Table 5).
Discussion
Main findings of the study
Many previous studies have investigated the relation-
ships between abdominal fat (visceral or subcutaneous)
and cardiometabolic risk factors [9, 10, 12, 13], epicar-
dial fat and cardiometabolic risk factors [14, 16, 17],
epicardial fat and subclinical atherosclerosis [25], intra-
hepatic fat and cardiometabolic risk factors and epicar-
dial fat with CAC score [9, 16, 26–28]. However, none of
these studies comprehensively examined the relative
contributions of abdominal fat (including visceral sub-
cutaneous fat) and cardiac fat (including epicardial,
Table 1 Clinical characteristics and measurements of various
adipose tissues in study participants (n = 208)
Age (years) 54.94 ± 9.05
Men (male) 79 %
Waist circumference (cm) 89.17 ± 8.90
BMI (kg/m2) 24.90 ± 3.36
HDL-C (mg/dL) 41 (18, 201)
Triglycerides (mg/dL) 130 (44, 2182)
Diabetes mellitus (%) 23 %
Current smokers (%) 45 %
Hypertension (%) 40 %
Number of metabolic components 2.35 ± 1.32
Agatston score 8.50 (44,2182)
Total volume of AVAT (mm3) 1129.09 ± 530.62
Total volume of PAT (mm3) 219.29 ± 90.02
Total volume of EAT (mm3) 121.33 ± 45.65
EATth-LAVG (mm) 15.92 ± 4.47
EATth-RAVG (mm) 17.08 ± 3.74
EATth-AIVG (mm) 8.36 ± 10.96
Data are presented as mean ± SD or median (min; max), depending
on distribution
BMI body mass index, HDL high density lipoprotein, AVAT abdominal visceral
adipose tissue, SAT abdominal subcutaneous adipose tissue, EAT epicardial
adipose tissue, PAT paracardial adipose tissue, EATth-LAVG EAT thickness at left
AV(atrioventricular) groove, EATth-RAVG EAT thickness at right
AV(atrioventricular) groove, EATth-AIVG EAT thickness at anterior IV
(interventricular) groove
Wu et al. BMC Cardiovascular Disorders  (2016) 16:20 Page 4 of 9
Fig. 2 (See legend on next page.)
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pericardial and regional-specific cardiac fat) on the car-
diometabolic risks. This is the first study to investigate
different distribution of abdominal and cardiac fat and
to correlate the amount fat deposits with variously car-
diometabolic risks simultaneously. Our study demon-
strated that the total volume of AVAT most strongly
correlates with the number of metabolic syndrome com-
ponents, BMI and waist circumference, whereas cardiac
fat, especially EATth-LAVG, is strongly associated with
the severity of Agatston score. These findings imply that
AVAT may contribute to metabolic syndrome, while
regional-specific cardiac adipose tissue (EATth-LAVG)
may contribute to coronary atherosclerosis, measured by
the severity of Agatston score. Furthermore, the present
findings also confirm previous evidences that ectopic fat
depots including VAT, intrahepatic fat, and intramuscu-
lar fat with predominantly potential systemic effects and
associated with increased metabolic risk. In contrast,
ectopic fat depots including pericardial and perivascular
fat are postulated to have a predominantly potential local
toxic effect with increased cardiovascular risks [5, 8]. In
addition, our study further demonstrated that regional-
specific cardiac adipose tissue may predisposes to athero-
sclerosis measured by Agatston score on a four ranking
scale. This finding is also supported by our previous study
and other studies [18, 21, 29].
Global or regional adiposity in cardiometabolic risk
factors
Recent studies have shown independent effects of global
visceral adipose tissue on cardiometabolic risks [9, 10, 30],
and other authors have shown that increased regional or
peri-coronary EAT predicts both cardiovascular disease
and metabolic syndrome [16–18]. In our study, clusters of
cardiometabolic risk factors and various measurements of
adipose tissue were identified by factor analysis. We de-
fined the term The factor 1(defined as volumetric abdom-
inal or cardiac adiposity-metabolic factor, and be more
representative of global fat-metabolic factor) explained the
maximum variance (49.91 %) and is in concordance with
the fact that global adipose tissues including total volume
of AVAT, EAT and PAT are more associated metabolic
syndrome components, BMI and WC. Among these pa-
rameters, total volume of AVAT showed the strongest cor-
relation with metabolic risks. The factor 2 (define as
regional cardiac fat-CAD factor) explained the maximum
variance (15.10 %), and EATth-LAVG is a most important
contributor of developing coronary artery disease. Most
importantly, it is postulated that global adipose tissue
could contribute to metabolic syndrome and regional car-
diac adipose tissue could contribute more to CAD. These
observations were unique in this study never reported be-
fore. We used factor analysis to concurrently investigate
the clustering of various measurements of adipose tissue
that are thought to be important components of cardio-
metabolic risks. Two expected factors emerged explaining
65 % of the variance. The current study results clearly
demonstrate, as far as we know for the first time, that dif-
ferent effects and correlation coefficient of global and re-
gional fat distribution on cardiometabolic risk factors
concurrently. The current study results suggest, as far as
we know for the first time, that global fat depots could re-
flect a contribution to a systemic effect on metabolic syn-
drome while regional-specific cardiac fat depots may exert
major local toxic effects on coronary artery disease. This
finding is also supported by previous theory. And for the
(See figure on previous page.)
Fig. 2 a The general linear model was used to test the linear trend of measurements of abdominal and cardiac fat according to the number of
metabolic syndrome components. The volumetric and thickness measurement of abdominal and cardiac fat in relation to the number of
metabolic syndrome components (P for trend <0.0001 in the AVAT, PAT, and EAT group; P for trend <0.001 in the EATth-LAVG group). b The
general linear model was used to test the linear trend of measurements of abdominal and cardiac fat according to the Agatston score on a four
ranking scale. The volumetric and thickness measurement of abdominal and cardiac fat in relation to coronary artery calcium (Agatston score on
a four ranking scale, P for trend <0.0001 in the AVAT, PAT, and EAT group; P for trend <0.0001 in the EATth-LAVG group)
Table 2 Correlation between various cardiac and abdominal adipose tissue measurements and cardiomeatbolic profiles
BMI Waist circumference Metabolic syndrome components Agatston score on a four ranking scale Agatston score
Total volume of AVAT 0.706** 0.775** 0.519** 0.169* 0.064
Total volume of PAT 0.529** 0.629** 0.382** 0.250** 0.109
Total volume of EAT 0.487** 0.526** 0.264** 0.127 0.083
EATth-LAVG 0.275** 0.239** 0.250** 0.307** 0.287**
EATth-RAVG 0.059** 0.116 −0.014 0.046 0.100
EATth-AIVG 0.052** 0.074 0.052 −0.060 −0.019
Abbreviation: as Table 1
*p <0.01
**p < 0.001
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first time, this theory has been well addressed in different
impacts of ectopic abdominal and cardiac fat deposits on
cardiometabolic risks in a direct head-to-head
comparison.
Pathophysiology
Adipose tissue is a metabolically active endocrine organ
that secretes and regulates multiple adipocytokines in-
cluding leptin, Interleukin-6 (IL-6), tumor necrosis
factor-α (TNF-α), resistin, adiponectin, monocyte
chemoattractant protein-1 (MCP-1) and free fatty acids
(FFA), and to have potential systemic or local effects on
cardiometabolic risks, determined by differential distri-
bution of ectopic fat deposits [5, 31–33]. The mechan-
ism by which the different distribution of ectopic fat
deposits associated with cardiometabolic risks is cur-
rently not well-established. Recent research has re-
vealed that increased abdominal visceral fat
accumulation provides excessive systemic free fatty
acid and inflammatory cytokine in the portal vein,
which accelerates insulin resistance and increased risk
of metabolic syndrome [7, 34, 35].
In contrast to the excessive abdominal visceral fat de-
pots with predominantly systemic metabolic effects, we
found that regional-specific ectopic cardiac fat depots in
EATth-LAVG, instead of total volume of EAT or PAT, is
the most important parameter of EAT adiposity in pre-
diction of atherosclerosis, independently even after ad-
justment for conventional risk factors and CAC score.
Because EAT asymmetrically covers 80 % of the heart’s
surface, especially in the coronary groove segments
along the course of the epicardial coronary vessels, we
could postulate that excessive regional cardiac fat de-
posits (especially in EATth-LAVG) may play a role in
pathogenesis of CAD by diffusion of EAT paracrine me-
tabolites through thin-walled coronary venous networks
embedded in left AVG. and drainage into the coronary
sinus and exert local toxic effects on coronary arteries
atherosclerosis. This finding is also supported by our
previous study and other studies [17, 21, 36].
Strengths and limitation
This study has several strengths. First, this is the first
comprehensive study to investigate different distribution
of abdominal and cardiac fat (including total volume of
AVAT, EAT, PAT and regional-specific cardiac fat simul-
taneously, and to compare the different impacts on car-
diometabolic risks simultaneously. Second, we measured
total volume of abdominal and cardiac adipose tissue,
which might be more representative of global adiposity
instead of measuring total fat area as described in previ-
ous studies [37, 38]. Third, we measured various fat par-
ameter in the same subject at the same time in a direct
head-to head comparison of the different abdominal and
Table 3 Factor analysis of different ectopic visceral adiposity
and cardiometabolic risks
Characteristic Factor 1 Factor 2
Waist circumference 0.881 −0.156
BMI 0.841 −0.228
Metabolic components 0.570 0.188
Agatston score 0.157 0.823
Total volume of AVAT 0.890 −0.136
Total volume of PAT 0.809 0.059
Total volume of EAT 0.702 −0.046
EATth-LAVG 0.467 0.629
Percentage of total variance explained 49.91 15.10
Cumulative % 49.91 65.01
Factor loading above 0.5 (positive or negative) are considered high
Abbreviation: as Table 1
Table 4 Multivariate binary logistic regression analysis for
predictors of presence of metabolic syndrome
Predictora OR 95 % CI P value
Age (years) 1.039 0.996–1.084 .074
Gender (male) 0.196 0.063–0.614 .154
Waist circumference (cm) 1.010 0.963–1.067 .051
Total volume of AVAT (mm3) 1.200 1.080–1.320 <0.001
Total volume of PAT (mm3) 1.002 0.991–1.013 .747
Total volume of EAT (mm3) 0.995 0.984–1.006 .378
EATth-LAVG (mm) 0.954 0.871–1.046 .316
Table 5 Multivariate binary logistic regression analysis for
predictors of Agatston score > 400 or not
Predictora OR 95 % CI P value
Age (years) 1.10 1.065–1.143 <0.001
Gender (male) 0.18 0.070–0.496 .001
Waist circumference (cm) 1.02 0.966–1.070 .528
Hypertension 0.56 0.314–0.979 .059
Diabetes mellitus 0.46 0.237–0.912 .026
HDL-C (mg/dL) 0.99 0.979–1.018 .858
Triglycerides (mg/dL) 1.00 0.998–1.002 .863
Current smokers 0.93 0.508–1.707 .819
Total volume of AVAT (mm3) 0.99 0.998–1.000 .303
Total volume of PAT (mm3) 0.99 0.999–1.015 .088
Total volume of EAT (mm3) 0.99 0.986–1.002 .142
EATth-LAVG (mm) 1.11 1.034–1.184 .004
Dependent variable: a Adjusted for conventional CAD risk factors (age, gender,
diabetes mellitus, hypertension, smoking habit, waist circumstance, HDL-C and
serum triglyceride) and Agatston score. CAD: coronary artery disease; others,
see Table 1
Wu et al. BMC Cardiovascular Disorders  (2016) 16:20 Page 7 of 9
cardiac fat deposits with cardiometabolic risks, instead
of indirect comparison in previous literature review.
Some limitation of this study must be taken into con-
sideration. Due to the cross-sectional study design, the
results, while showing correlations, do not imply causal-
ity between different ectopic fat depots and cardiometa-
bolic risks, We did not measure parameters of insulin
resistance or inflammation such as insulin sensitivity
index or high-sensitivity C-reactive protein. Therefore,
the mechanism of insulin resistance and global inflam-
mation related to abdominal or cardiac visceral fat and
cardiometabolic risks cannot be directly analyzed.
Conclusion
In conclusion, total AVAT, EAT and PAT are associated
with increasing number of metabolic syndrome compo-
nents; while regional cardiac fat, especially EATth-LAVG,
has stronger association with coronary atherosclerosis,
measured by the severity of Agatston score. Our results
suggest that global adiposity (especially AVAT) potentially
has systemic inflammatory effect and contributes to the
development of metabolic syndrome, while regional
specific cardiac adiposity (especially measured by EATth-
LAVG) may exert potentially local toxic effects on coron-
ary arteries. Quantitative measurements of ectopic
abdominal and regional-specific cardiac fat may poten-
tially improve cardiometabolic risk assessment.
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